SRC and neoplasm: As indicated in Supplementary Figure S1, SKLB-178 potently inhibited the phosphorylation levels of EGFR and Src just as depicted in in vitro assays, leading to a significant decrease in proliferating tumor cells (Ki67-positive cells) and substantial increase in apoptotic cells (TUNEL-positive cells) compared with the corresponding control in HCC827 and A549 models (Figure 5D and 5E).